Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

29,905 total articles

Helsinki stocks slip as Telecoms, Utilities and Tech weigh on index

Helsinki stocks slip as Telecoms, Utilities and Tech weigh on index

Finnish equities closed lower Wednesday, with the OMX Helsinki 25 dropping 1.06% after losses in Telecoms, Utilities and Technology sectors. Hiab, Huhtamaki and Valmet were among the session's gainers, while Elisa, Nokia and Fortum posted the largest declines. Commodity benchmarks and major currencies moved modestly lower during the trading session…

Yankees in Advanced Talks for Nearly $3 Billion Financing from Apollo

Yankees in Advanced Talks for Nearly $3 Billion Financing from Apollo

The New York Yankees are engaged in advanced negotiations to obtain close to $3 billion in financing from Apollo Global Management. The proposed transaction, led by Apollo’s sports investment arm, would be structured mainly as debt with a limited equity stake. Yankee Global Enterprises, controlled by Hal Steinbrenner and family, would use part of t…

Anthropic Lines Up Investor Meetings as It Prepares for Possible October IPO

Anthropic Lines Up Investor Meetings as It Prepares for Possible October IPO

Anthropic PBC has started arranging private investor meetings with major banks as it moves toward a potential initial public offering as early as October. The company has previously filed a confidential draft registration with the SEC; underwriters Morgan Stanley, Goldman Sachs and JPMorgan are conducting preliminary sessions to measure institution…

Buffett Says Speculation Is Crowding Out Value in Today's Market

Buffett Says Speculation Is Crowding Out Value in Today's Market

Warren Buffett told CNBC that a rise in speculative trading - including one-day options and leveraged products - has made it difficult to locate traditional value investments. The 95-year-old investor said markets now reward gamblers, and noted opportunities can be fleeting or extremely scarce. Market highs this year have coexisted with an energy s…

Loop Capital Starts Adyen at Hold, Flags Need to Trim Revenue Targets

Loop Capital Starts Adyen at Hold, Flags Need to Trim Revenue Targets

Loop Capital Markets opened coverage of Dutch payments processor Adyen with a Hold rating and a €900 price target, arguing the company’s medium-term net revenue growth goal will likely need to be lowered amid a slowdown in wallet share expansion. The broker models slower net revenue growth and slightly lower margin assumptions than consensus, and h…

Electrovaya Shares Jump After Amazon Warrant Agreement

Electrovaya Shares Jump After Amazon Warrant Agreement

Electrovaya Inc. shares rose sharply after the company announced a commercial agreement and a warrant arrangement with Amazon. The pact is intended to accelerate deployment of Electrovaya’s Infinity Battery Technology in material handling and may extend to robotics and energy storage. Amazon was granted warrants for up to 13,880,345 common shares t…

Morgan Stanley Posts Record Quarter but Shares Slip in Pre-Market

Morgan Stanley Posts Record Quarter but Shares Slip in Pre-Market

Morgan Stanley reported a landmark quarter with record revenue of $21.35 billion, $3.46 in earnings per share, a 69% jump in equity trading revenue to $6.3 billion, and strong wealth-management inflows. Despite those results, the stock fell 1.3% in pre-open trading as stretched valuation and an already-elevated market left investors taking profits.

Merck Shares Jump After Dual Trial Successes Bolster Keytruda Outlook

Merck Shares Jump After Dual Trial Successes Bolster Keytruda Outlook

Merck shares moved higher in pre-market trading after its KEYNOTE-C93 Phase 3 trial met the primary endpoint for progression-free survival in mismatch repair deficient advanced or recurrent endometrial cancer, and a partner-led Phase 3 study combining sacituzumab tirumotecan with pembrolizumab also met its primary endpoint in PD-L1 negative non-sma…